Claims for Patent: 10,421,954

Summary for Patent: 10,421,954

Title:	Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same
Abstract:	Novel hybrid polymers are disclosed that have a structure represented by the following formula I: ##STR00001## wherein Abiotic oligomer, Polypeptide, X, Y, and R.sup.1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.
Inventor(s):	Kirshenbaum; Kent (New York, NY), Levine; Paul (Los Angeles, CA), Craven; Timothy (Randolph, NJ)
Assignee:	NEW YORK UNIVERSITY (New York, NY)
Application Number:	15/281,202
Patent Claims:	1. A hybrid polymer comprising an abiotic oligomer segment and a polypeptide segment; and wherein the polypeptide segment comprises at least one serine or threonine residue at its N-terminus, and the abiotic oligomer segment is bonded to the polypeptide through the serine or the threonine residue; and wherein i) the said abiotic oligomer segment comprises N-substituted glycine peptoid oligomers, beta-peptoids, beta-peptides, alternating alpha/beta peptides, gamma-peptides, pyridine oligoamides, quinoline oligoamides, aryl oligoamides, aedemers, peptide nucleic acids, other abiotic oligoamides, sulfonamidopeptides, aminoxy acid oligomers, hydrazone-linked pyrimidines, oligo-ureidophthalimides, triazine-based oligomers, triazole-based oligomers, oligooxopiperazine oligomers, and oligoureas or any combinations thereof; and the polypeptide segment is a parathyroid hormone 1-34 or PTH (1-34) polypeptide; or ii) the hybrid polymer is Compound 9, Compound 10, Compound 11, Compound 12, Compound 13, Compound 14, Compound 15, Compound 16, Compound 17, Compound 18, Compound 19, Compound 20, Compound 21, Compound 22, Compound 23, or Compound 24 ##STR00059## ##STR00060## ##STR00061## ##STR00062## ##STR00063## or a pharmaceutically acceptable salt, stereoisomer, isotopic variant or tautomer thereof. 2. The hybrid polymer according to claim 1, wherein the hybrid polymer is according to formula I: ##STR00064## or a pharmaceutically acceptable salt, stereoisomer, isotopic variant or tautomer thereof; wherein abiotic oligomer is selected from N-substituted glycine peptoid oligomers, beta-peptoids, beta-peptides, alternating alpha/beta peptides, gamma-peptides, pyridine oligoamides, quinoline oligoamides, aryl oligoamides, aedemers, peptide nucleic acids, other abiotic oligoamides, sulfonamidopeptides, aminoxy acid oligomers, hydrazone-linked pyrimidines, oligo-ureidophthalimides, triazine-based oligomers, triazole-based oligomers, oligooxopiperazine oligomers, and oligoureas; ##STR00065## the group is a serine or threonine residue; Y is H or acetyl; R.sup.1 is H or methyl; and ##STR00066## is -PTH(2-34). 3. The hybrid polymer according to claim 1, wherein the hybrid polymer is according to formula II: ##STR00067## or a pharmaceutically acceptable salt, stereoisomer, isotopic variant or tautomer thereof; wherein X is hydroxyl, alkoxy, amino or substituted amino; Y is H or acetyl; R.sup.1 is H or methyl; each R.sup.2 is independently selected from a group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; and the subscript m is an integer from 2-200; and ##STR00068## is -PTH(2-34). 4. The hybrid polymer according to claim 2, wherein R.sup.1 is H. 5. The hybrid polymer according to claim 2, wherein R.sup.1 is Me. 6. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently Me, Et, n-Pr, i-Pr, n-Bu, sec-Bu, or i-Bu. 7. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently phenyl or benzyl, unsubstituted or substituted with one or more groups selected from alkyl, halo, hydroxy, amino, nitro, and alkoxy. 8. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently phenethyl, unsubstituted or substituted with one or more groups selected from alkyl, halo, hydroxy, amino, nitro, and alkoxy. 9. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently 2-naphthyl, unsubstituted or substituted with one or more groups selected from alkyl, halo, hydroxy, amino, nitro, and alkoxy. 10. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently 2,2-diphenylethyl, unsubstituted or substituted with one or more groups selected from alkyl, halo, hydroxy, amino, nitro, and alkoxy. 11. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently furanyl or thienyl, unsubstituted or substituted with one or more groups selected from alkyl, halo, hydroxy, amino, nitro, and alkoxy. 12. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, or 6-aminohexyl. 13. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently 3-aminopropyl. 14. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently guanidinoalkyl. 15. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently guanidinomethyl, 2-guanidinoethyl, 3-guanidinopropyl, 4-guanidinobutyl, 5-guanidinopentyl, or 6-guanidinohexyl. 16. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently 4-guanidinobutyl. 17. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently imidazolylmethyl, 2-imidazolylethyl, 3-imidazolylpropyl, 4-imidazolylbutyl, 5-imidazolylpentyl, or 6-imidazolylhexyl. 18. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently methyl, n-propyl, n-butyl, n-pentyl, and n-hexyl, substituted with pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, triazolyl, or tetrazolyl. 19. The hybrid polymer according to claim 3, wherein each of R.sup.2 is independently Me, i-Pr, i-Bu, sec-Bu, phenethyl, 4-hydroxyphenethyl, benzimidazol-3-ylmethyl, thiomethyl, methylthioethyl, hydroxymethyl, aminopropyl, guanadinopropyl, or imdazo-4-yl methyl. 20. The hybrid polymer according to claim 2, wherein Y is acyl, unsubstituted or substituted with cycloalkyl, or phenyl. 21. The hybrid polymer according to claim 2, wherein Y is acetyl, lauroyl, tridecanoyl, myristoyl, pentadecanoyl, palmitoyl, caproyl, benzoyl, cetyl, decyl, acetyl, phenyl acetyl, cyclohexyl acetyl, valeroyl, or glucuronyl residue. 22. The hybrid polymer according to claim 2, wherein m is an integer between 2-200, 2-100, 2-50, 2-30, 2-20, 2-10, or 2-5. 23. The hybrid polymer according to claim 1, wherein the hybrid polymer selected from a group of compounds consisting of Compound 9, Compound 10, Compound 11, Compound 12, Compound 13, Compound 14, Compound 15, Compound 16, Compound 17, Compound 18, Compound 19, Compound 20, Compound 21, Compound 22, Compound 23, and Compound 24: ##STR00069## ##STR00070## ##STR00071## ##STR00072## or a pharmaceutically acceptable salt, stereoisomer, isotopic variant or tautomer thereof. 24. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the hybrid polymer of claim 1. 25. The pharmaceutical composition of claim 24, wherein the carrier is a parenteral carrier, oral or topical carrier. 26. A method for treating osteoporosis in a subject in need thereof, the method comprising administering a therapeutically effective amount of a hybrid polymer of claim 1 or a pharmaceutical composition thereof to the subject.

Details for Patent 10,421,954

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2033-05-20